Literature DB >> 14962320

Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV.

S L Orton1, S L Stramer, R Y Dodd, M J Alter.   

Abstract

BACKGROUND: In 1999, NAT of blood donations was implemented to detect "window-period" infections. Blood donors who have confirmed NAT results positive for the presence of HCV in the absence of anti-HCV are likely to have been recently infected. Of over 26.8 million donations tested between March 3, 1999, and March 31, 2003, 810 were HCV-reactive by NAT. A subset of these donors was assessed for recent exposure risk. STUDY DESIGN AND METHODS: All anti-HCV- blood donors with reactive, unconfirmed HCV NAT results were invited to participate in a study that included an extensive demographic and risk questionnaire. Confirmed HCV+ cases were compared to HCV- (falsely positive) controls for histories of potential risk factors during the 6 months before donation.
RESULTS: Recent injection drug use (IDU) was independently associated with HCV infection (29.2% vs. 0% of cases vs. controls, p < 0.001). In addition, likely sources were identified for three other cases (4.6%), including occupational exposure, sexual contact with an HCV-infected partner (who was an IDU), and perinatal exposure, none of which was known to the donors at the time of donation. Incarceration was independently associated with HCV infection among the group not reporting IDU and after removal of the three donors with likely sources of risk (14.6% vs. 1.3% of cases vs. controls, p < 0.001).
CONCLUSIONS: A likely risk, primarily IDU, was found for 43 percent of HCV+ donors whose infections were identified solely by NAT. Because the maximum efficiency of the donor history questions may have been reached, NAT will continue to be an important measure to interdict recently infected blood donors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962320     DOI: 10.1111/j.1537-2995.2004.00623.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

1.  Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients.

Authors:  Gayle Shimokura; Feng Chai; David J Weber; Gregory P Samsa; Guo-Liang Xia; Omana V Nainan; Leslie H Tobler; Michael P Busch; Miriam J Alter
Journal:  Infect Control Hosp Epidemiol       Date:  2011-05       Impact factor: 3.254

2.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

3.  Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland.

Authors:  Christoph Niederhauser; Jochen Gottschalk; Caroline Tinguely
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

4.  The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco.

Authors:  Keith A Hermanstyne; David R Bangsberg; Karen Hennessey; Cindy Weinbaum; Judith A Hahn
Journal:  J Public Health (Oxf)       Date:  2012-03-26       Impact factor: 2.341

5.  What weighs more-low compliance with self-deferral or minor medical procedures? Explaining the high rate of hepatitis C virus window-period donations in Poland.

Authors:  Michal Czerwinski; Piotr Grabarczyk; Malgorzata Stepien; Dorota Kubicka-Russel; Katarzyna Tkaczuk; Ewa Brojer; Magdalena Rosinska
Journal:  Transfusion       Date:  2017-05-28       Impact factor: 3.157

6.  Risk factors for retrovirus and hepatitis virus infections in accepted blood donors.

Authors:  Brian Custer; Debra Kessler; Farnaz Vahidnia; German Leparc; David E Krysztof; Beth Shaz; Hany Kamel; Simone Glynn; Roger Y Dodd; Susan L Stramer
Journal:  Transfusion       Date:  2014-12-04       Impact factor: 3.157

7.  Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.

Authors:  Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

8.  A Systematic Review of Interventions Used to Increase Blood Donor Compliance with Deferral Criteria.

Authors:  Julia C Cutts; Brendan Quinn; Clive R Seed; George Kotsiou; Ruth Pearson; Nick Scott; David P Wilson; Mary Ellen Harrod; Lisa Maher; Sharon Caris; Alex J Thompson; Michael Farrell; Joanne Pink; Margaret E Hellard
Journal:  Transfus Med Hemother       Date:  2020-07-23       Impact factor: 3.747

Review 9.  Surveillance of transfusion-transmissible infections comparison of systems in five developed countries.

Authors:  Sheila F O'Brien; Shimian Zou; Syria Laperche; Lisa J Brant; Clive R Seed; Steven H Kleinman
Journal:  Transfus Med Rev       Date:  2011-09-25

10.  Author's Reply.

Authors:  Hans Van Remoortel; Emmy De Buck
Journal:  Vox Sang       Date:  2019-06-17       Impact factor: 2.144

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.